European Biotech Acquisition (European Biotech Acquisition) Debt-to-Asset : 0.00 (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Debt-to-Asset?

European Biotech Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. European Biotech Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. European Biotech Acquisition's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was $129.75 Mil. European Biotech Acquisition's debt to asset for the quarter that ended in Dec. 2022 was 0.00.

European Biotech Acquisition Debt-to-Asset Historical Data

The historical data trend for European Biotech Acquisition's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Debt-to-Asset Chart

European Biotech Acquisition Annual Data

Trend

Dec21

Dec22

Debt-to-Asset

European Biotech Acquisition Quarterly Data
	Jan21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of European Biotech Acquisition's Debt-to-Asset

For the Shell Companies subindustry, European Biotech Acquisition's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

European Biotech Acquisition's Debt-to-Asset Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Debt-to-Asset falls into.

European Biotech Acquisition Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

European Biotech Acquisition's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	129.753
	=	0.00

European Biotech Acquisition's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	129.753
	=	0.00

European Biotech Acquisition (NAS:EBACU) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

European Biotech Acquisition Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

European Biotech Acquisition (European Biotech Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

EPFL Innovation Park Building, Lausanne, CHE, 1015

Website

https://www.lspvc.com

European Biotech Acquisition Corp is a blank check company.

Executives

Mohammad Sohail Fazeli	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen	director	RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo	officer: Chief Executive Officer	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas	officer: Chief Financial Officer	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter	director	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV

European Biotech Acquisition (European Biotech Acquisition) Headlines

From GuruFocus

European Biotech Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing May 6, 2021

By Business Wire Business Wire • 05-04-2021

European Biotech Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report

By Business Wire Business Wire • 06-04-2021